By the European Society for Medical Oncology (ESMO) team
Join the EMUC21 session ‘Radioligand therapy: multidisciplinary collaboration for health system readiness’ on 25 November, from 16:30 to 18:00.
The session, hosted by The Health Policy Partnership (HPP), will discuss radioligand therapy – an innovative and targeted approach in oncology – and its potential role in prostate cancer care. This event is especially significant, given the recent release of data from the VISION trial on the use of radioligand therapy for advanced prostate cancer.
Radioligand therapy’s integration
With potential regulatory approval for radioligand therapy in prostate cancer on the horizon, we must carefully plan how the approach is integrated into existing care pathways. The need to proactively prepare for radioligand therapy’s integration from a multidisciplinary and systems perspective will be highlighted during this session. We hope to catalyse discussions on what a ready policy environment for radioligand therapy looks like at both the EU and national levels.
The session will see Professor Hein Van Poppel (European Association of Urology) discuss why a multidisciplinary approach to prostate cancer care is important. Dr John Buscombe (British Nuclear Medicine Society) will speak on what radioligand therapy is and its potential use in prostate cancer. Erik Briers (Europa Uomo) will also analyse the potential impact of radioligand therapy from a patient perspective.
Radioligand Therapy Readiness Assessment Framework
Christine Merkel (HPP) will then discuss how the recently launched Radioligand Therapy Readiness Assessment Framework can be used to support proactive and data-driven policy development for radioligand therapy, with key findings and policy priorities around prostate cancer in the UK and US being presented. Ms Merkel will go on to moderate a panel discussion with Dr Andreas Charalambous (European Oncology Nursing Society), Dr Jolanta Kunikowska (European Association of Nuclear Medicine), Dr Boris Hadaschik (Essen University Hospital), Professor Silke Gillessen (Oncology Institute of Southern Switzerland) and Professor Gert De Meerleer (UZ Leuven) to discuss how the clinical community can create a ready and multidisciplinary system for radioligand therapy. The panel will also take questions from the audience.
Explore all that the EMUC21 scientific programme has to offer you here. Residents, medical students, nurses, full-time researchers, and patient advocates can benefit from discounted fees. Register today and save here!
Please visit www.radioligandtherapy.com for further information on the Radioligand Therapy Readiness Assessment Framework.